RemeGen Co. Ltd. A (688331) fair value: what the stock is really worth
We calculate from audited financials what RemeGen Co. Ltd. A is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch RemeGen Co. Ltd. A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 18, 2026.
How to read this chart
54‑month range ¥22.59 – ¥153.26 · fair‑value band ¥14.71 – ¥33.46 · the ¥114.84 price screens above the ¥23.19 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 18, 2026.
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.
Show more
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Stock analysis
RemeGen Co. Ltd. A (688331) currently trades at ¥114.84, while our model-based Fair Value estimate is ¥23.19, implying the stock looks roughly 395.3% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥59.93 per share, and 0 of the 15 models we run sit above the ¥114.84 price.
Bear case: the Asset-Based group reads lowest at ¥2.83, and 15 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥14.71 (bear) to ¥33.46 (bull), the price of ¥114.84 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
RemeGen Co. Ltd. A reported revenue of 3.3B CNY in FY2025 versus 1.4B CNY in FY2021, a compound +22.9%/yr. Reported net income was 709M CNY in FY2025, compounding +26.5%/yr from FY2021.
Key figures
Market cap 75.8B CNY (≈ $11.3B) · P/E ratio 88.3 · P/S ratio 19.2 · EPS (TTM) ¥1.29 · Net margin 21.8% · Return on equity 45.3% · Return on assets (EBIT) −11.3% · Operating margin −3.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 95% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −80%, 688331 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥2.83 to ¥61.17). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ¥14.71Fair Value ¥23.19Bull ¥33.46
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.9330 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+89.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.5%
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+124.5%
’18
’19
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+17.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.9%
Dividend (yield on the price)0.0%
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−15,706% → 22%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 653 stocks
Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score64 · Top 25%
Fair Value upside−81% · Bottom 25%
Profitability
Return on equity (TTM)45% · Top 25%
Return on assets3% · Top 25%
Net margin (TTM)38% · Top 25%
Operating margin (TTM)−3% · Below median
Growth and dividend
Revenue growth25% · Above median
Balance sheet
Debt / equity0.32× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)88.3× · Priciest 25%
P/B32.66× · Priciest 25%
P/S (TTM)22.41× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)100· sector 0
HEALTH (low debt)84· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "RemeGen Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688331
Frequently asked questions
Is RemeGen Co. Ltd. A (688331) overvalued or undervalued?
As of Sep 18, 2026, our model estimates a fair value of ¥23.19 versus a price of ¥114.84, about −80% upside (overvalued).
What is the fair value of 688331?
Our model-based fair value for RemeGen Co. Ltd. A is ¥23.19 (as of Sep 18, 2026), built from audited fundamentals. The current price: ¥114.84.
What is the quality score of 688331?
RemeGen Co. Ltd. A has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for RemeGen Co. Ltd. A (688331)?
Our model-based price target is the fair value of ¥23.19 (as of Sep 18, 2026) from 15 valuation models. Cautious scenario ¥14.71, optimistic scenario ¥33.46. It is a calculation from audited fundamentals, not an analyst target.
What is the RemeGen Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥23.19, about −80% upside versus a price of ¥114.84 (overvalued). Cautious scenario ¥14.71, optimistic scenario ¥33.46. The calculation is refreshed regularly with new filings.
What is the revenue of RemeGen Co. Ltd. A (688331)?
RemeGen Co. Ltd. A reported trailing-twelve-month revenue of about 3.4B CNY (latest available figure, as of Sep 18, 2026).
What is the intrinsic value of RemeGen Co. Ltd. A (688331)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For RemeGen Co. Ltd. A it is ¥23.19 per share (as of Sep 18, 2026), against a price of ¥114.84. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is RemeGen Co. Ltd. A stock overvalued or undervalued in 2026?
As of Sep 18, 2026, 688331 trades above its calculated fair value: price ¥114.84, fair value ¥23.19, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688331?
No. The price is what the market pays today (¥114.84); the fair value is what the company's own numbers justify (¥23.19). For RemeGen Co. Ltd. A the two are ¥91.65 per share apart. That gap is exactly why we show both numbers side by side.
How much is RemeGen Co. Ltd. A worth?
The market values RemeGen Co. Ltd. A at about 75.8B CNY (market capitalisation, as of Sep 18, 2026). Per share that is ¥114.84; our models calculate a fair value of ¥23.19 per share.
What do the bullish and bearish scenarios say about 688331?
Our models span a range for RemeGen Co. Ltd. A: cautious scenario ¥14.71, base ¥23.19, optimistic ¥33.46 per share (as of Sep 18, 2026, price ¥114.84). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688331?
RemeGen Co. Ltd. A trades at a price-to-earnings ratio of 88.3 (as of Sep 18, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥23.19 is built from several models across several years. Other multiples: P/B 32.7, P/S 22.4.
How solid is the balance sheet of RemeGen Co. Ltd. A (688331)?
Balance-sheet figures for RemeGen Co. Ltd. A (as of Sep 18, 2026): return on equity 45.3%, debt of 0.32 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is 688331 from its 52-week high?
RemeGen Co. Ltd. A trades at ¥114.84, about 27% below its 52-week high of ¥156.79 and 95% above the low of ¥58.85 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of ¥23.19 is for.
Which stocks are comparable to RemeGen Co. Ltd. A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is RemeGen Co. Ltd. A stock attractive at the current price?
The data as of Sep 18, 2026: price ¥114.84, calculated fair value ¥23.19 (−80%), Quality Score 64/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688331 calculated?
We run RemeGen Co. Ltd. A through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥23.19, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. RemeGen Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of RemeGen Co. Ltd. A (688331)?
The closing price on Sep 18, 2026 was ¥114.84. Our model-based fair value is ¥23.19, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with RemeGen Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥33.46). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥14.71 to ¥33.46) leaves room in how you read the outcome.
Key figures of RemeGen Co. Ltd. A
How large is the market capitalisation of RemeGen Co. Ltd. A (688331)?
The market capitalisation of RemeGen Co. Ltd. A is 75.8B CNY (≈ $11.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of RemeGen Co. Ltd. A (688331)?
The price-to-sales ratio of RemeGen Co. Ltd. A is 19.2 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of RemeGen Co. Ltd. A (688331)?
Earnings per share at RemeGen Co. Ltd. A are ¥1.29 (price ÷ EPS = P/E 88.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of RemeGen Co. Ltd. A (688331)?
The net margin of RemeGen Co. Ltd. A is 21.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of RemeGen Co. Ltd. A (688331)?
The return on equity (ROE) of RemeGen Co. Ltd. A is 45.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of RemeGen Co. Ltd. A (688331)?
On an EBIT basis the return on assets of RemeGen Co. Ltd. A is −11.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of RemeGen Co. Ltd. A (688331)?
The operating margin of RemeGen Co. Ltd. A is −3.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at RemeGen Co. Ltd. A (688331)?
Revenue at RemeGen Co. Ltd. A is growing +24.8% versus a year earlier (3y avg +61.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does RemeGen Co. Ltd. A (688331) generate?
The free cash flow of RemeGen Co. Ltd. A is −144M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does RemeGen Co. Ltd. A (688331) carry?
The net debt of RemeGen Co. Ltd. A is 272M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch RemeGen Co. Ltd. A in the live analysis
One click puts RemeGen Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
